Why aren't physicians prescribing more buprenorphine?

Research output: Contribution to journalArticle

Abstract

Background & objective Buprenorphine is an underutilized pharmacotherapy that can play a key role in combating the opioid epidemic. Individuals with opioid use disorder (OUD) often struggle to find physicians that prescribe buprenorphine. Many physicians do not have the waiver to prescribe buprenorphine, and a large proportion of physicians that are waivered do not prescribe to capacity. This study aimed to quantitatively understand why physicians do not utilize buprenorphine for the treatment of OUD more frequently. Methods Physicians (n = 558) with and without the waiver to prescribe buprenorphine were surveyed about perceived drawbacks associated with prescribing buprenorphine. Furthermore, resources were identified that would encourage those without the waiver to obtain it, and those with the waiver to accept more new patients. The survey was distributed online to physicians in the spring/summer of 2016 via the American Society for Addiction Medicine and American Medical Association listservs. Results and conclusions A logistic regression analysis was used to identify reasons that respondents indicated no willingness to increase prescribing (χ2(4) = 73.18, p < 0.001); main reasons were lack of belief in agonist treatment (OR 3.98, 95% CI, 1.43 to 11.1, p = 0.008), lack of time for additional patients (OR 5.54, 95% CI, 3.5 to 8.7, p < 0.001), and belief that reimbursement rates are insufficient (OR 2.50, 95% CI, 1.3 to 4.8, p = 0.006). Differences between non-waivered and waivered physicians concerning attitudes toward buprenorphine treatment as well as resources that would increase willingness to prescribe are also discussed. Identifying barriers to buprenorphine utilization is crucial in expanding treatment options for individuals with OUD.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalJournal of Substance Abuse Treatment
Volume78
DOIs
StatePublished - Jul 1 2017

Fingerprint

Buprenorphine
Physicians
Opioid Analgesics
American Medical Association
Therapeutics
Logistic Models
Regression Analysis
Medicine
Drug Therapy

Keywords

  • Buprenorphine
  • Opioid maintenance treatment
  • Opioid use disorder
  • Physician

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Phychiatric Mental Health
  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Why aren't physicians prescribing more buprenorphine? / Huhn, Andrew; Dunn, Kelly.

In: Journal of Substance Abuse Treatment, Vol. 78, 01.07.2017, p. 1-7.

Research output: Contribution to journalArticle

@article{c0c8ed938ac846c9b6ccb75909f8e8a8,
title = "Why aren't physicians prescribing more buprenorphine?",
abstract = "Background & objective Buprenorphine is an underutilized pharmacotherapy that can play a key role in combating the opioid epidemic. Individuals with opioid use disorder (OUD) often struggle to find physicians that prescribe buprenorphine. Many physicians do not have the waiver to prescribe buprenorphine, and a large proportion of physicians that are waivered do not prescribe to capacity. This study aimed to quantitatively understand why physicians do not utilize buprenorphine for the treatment of OUD more frequently. Methods Physicians (n = 558) with and without the waiver to prescribe buprenorphine were surveyed about perceived drawbacks associated with prescribing buprenorphine. Furthermore, resources were identified that would encourage those without the waiver to obtain it, and those with the waiver to accept more new patients. The survey was distributed online to physicians in the spring/summer of 2016 via the American Society for Addiction Medicine and American Medical Association listservs. Results and conclusions A logistic regression analysis was used to identify reasons that respondents indicated no willingness to increase prescribing (χ2(4) = 73.18, p < 0.001); main reasons were lack of belief in agonist treatment (OR 3.98, 95{\%} CI, 1.43 to 11.1, p = 0.008), lack of time for additional patients (OR 5.54, 95{\%} CI, 3.5 to 8.7, p < 0.001), and belief that reimbursement rates are insufficient (OR 2.50, 95{\%} CI, 1.3 to 4.8, p = 0.006). Differences between non-waivered and waivered physicians concerning attitudes toward buprenorphine treatment as well as resources that would increase willingness to prescribe are also discussed. Identifying barriers to buprenorphine utilization is crucial in expanding treatment options for individuals with OUD.",
keywords = "Buprenorphine, Opioid maintenance treatment, Opioid use disorder, Physician",
author = "Andrew Huhn and Kelly Dunn",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.jsat.2017.04.005",
language = "English (US)",
volume = "78",
pages = "1--7",
journal = "Journal of Substance Abuse Treatment",
issn = "0740-5472",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Why aren't physicians prescribing more buprenorphine?

AU - Huhn, Andrew

AU - Dunn, Kelly

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background & objective Buprenorphine is an underutilized pharmacotherapy that can play a key role in combating the opioid epidemic. Individuals with opioid use disorder (OUD) often struggle to find physicians that prescribe buprenorphine. Many physicians do not have the waiver to prescribe buprenorphine, and a large proportion of physicians that are waivered do not prescribe to capacity. This study aimed to quantitatively understand why physicians do not utilize buprenorphine for the treatment of OUD more frequently. Methods Physicians (n = 558) with and without the waiver to prescribe buprenorphine were surveyed about perceived drawbacks associated with prescribing buprenorphine. Furthermore, resources were identified that would encourage those without the waiver to obtain it, and those with the waiver to accept more new patients. The survey was distributed online to physicians in the spring/summer of 2016 via the American Society for Addiction Medicine and American Medical Association listservs. Results and conclusions A logistic regression analysis was used to identify reasons that respondents indicated no willingness to increase prescribing (χ2(4) = 73.18, p < 0.001); main reasons were lack of belief in agonist treatment (OR 3.98, 95% CI, 1.43 to 11.1, p = 0.008), lack of time for additional patients (OR 5.54, 95% CI, 3.5 to 8.7, p < 0.001), and belief that reimbursement rates are insufficient (OR 2.50, 95% CI, 1.3 to 4.8, p = 0.006). Differences between non-waivered and waivered physicians concerning attitudes toward buprenorphine treatment as well as resources that would increase willingness to prescribe are also discussed. Identifying barriers to buprenorphine utilization is crucial in expanding treatment options for individuals with OUD.

AB - Background & objective Buprenorphine is an underutilized pharmacotherapy that can play a key role in combating the opioid epidemic. Individuals with opioid use disorder (OUD) often struggle to find physicians that prescribe buprenorphine. Many physicians do not have the waiver to prescribe buprenorphine, and a large proportion of physicians that are waivered do not prescribe to capacity. This study aimed to quantitatively understand why physicians do not utilize buprenorphine for the treatment of OUD more frequently. Methods Physicians (n = 558) with and without the waiver to prescribe buprenorphine were surveyed about perceived drawbacks associated with prescribing buprenorphine. Furthermore, resources were identified that would encourage those without the waiver to obtain it, and those with the waiver to accept more new patients. The survey was distributed online to physicians in the spring/summer of 2016 via the American Society for Addiction Medicine and American Medical Association listservs. Results and conclusions A logistic regression analysis was used to identify reasons that respondents indicated no willingness to increase prescribing (χ2(4) = 73.18, p < 0.001); main reasons were lack of belief in agonist treatment (OR 3.98, 95% CI, 1.43 to 11.1, p = 0.008), lack of time for additional patients (OR 5.54, 95% CI, 3.5 to 8.7, p < 0.001), and belief that reimbursement rates are insufficient (OR 2.50, 95% CI, 1.3 to 4.8, p = 0.006). Differences between non-waivered and waivered physicians concerning attitudes toward buprenorphine treatment as well as resources that would increase willingness to prescribe are also discussed. Identifying barriers to buprenorphine utilization is crucial in expanding treatment options for individuals with OUD.

KW - Buprenorphine

KW - Opioid maintenance treatment

KW - Opioid use disorder

KW - Physician

UR - http://www.scopus.com/inward/record.url?scp=85018473021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018473021&partnerID=8YFLogxK

U2 - 10.1016/j.jsat.2017.04.005

DO - 10.1016/j.jsat.2017.04.005

M3 - Article

C2 - 28554597

AN - SCOPUS:85018473021

VL - 78

SP - 1

EP - 7

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

SN - 0740-5472

ER -